Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Avandia's Heart Risk Higher Than Others in Its Class

A similar diabetes drug, Actos, doesn't seem to carry same dangers, study finds

By Steven Reinberg
HealthDay Reporter


Related Encyclopedia
 border=
Addison's Disease
Alzheimer's Disease
Aneurysms
Angina Pectoris
More...

Related Healthscout Videos
 border=
Shutting Down Tremor.
What's Your Stroke IQ?
Disaster Heart Attacks
Teaching Old Docs New Tricks
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Angioplasty
Coronary Bypass Surgery
Diabetes
More...

Related Drug Information
 border=
Accupril
Actonel
Actos
Altace
More...

Related News Articles
 border=
Deadly Stomach Bug Making Inroads Outside Hospitals
Sugar Shortens Life Span in Worms
CDC Finds U.S. 30th in Infant Mortality
Statins May Worsen Fatigue in Heart Failure Patients
More...

MONDAY, Nov. 24 (HealthDay News) -- The widely used diabetes drug Avandia -- already controversial because of cardiovascular side effects -- may be riskier than Actos, another drug in the same class, researchers reported Monday.

The risk of heart failure and death for older diabetics appears greater with Avandia (rosiglitazone) than with Actos (pioglitazone), both of which are part of a class of drugs called thiazolidinediones, Harvard University researchers said.

Text Continues Below



Avandia and Actos are used to lower blood sugar in patients with type 2 diabetes. Recent studies suggested that the risk for heart failure, death and heart attack were increased with Avandia, touching off a controversy that resulted in new FDA-mandated label warnings about the drug.

"By contrast, Actos did not appear to increase the risk of cardiac events," said lead researcher Dr. Wolfgang C. Winkelmayer, an assistant professor of medicine at Harvard Medical School. "One could get the impression that Actos led to the reduction of heart attacks."

Indirectly, people inferred that it might be better to use Actos, because Avandia has cardiovascular risks associated with it, Winkelmayer said.

"We did find that patients using rosiglitazone actually had an increased risk of mortality from any cause. We did not find a difference in heart attacks and strokes," Winkelmayer said. But, he added, more patients taking Avandia were hospitalized for heart failure.

Winkelmayer noted differences in drugs in the same class are not unusual. For example, cholesterol-lowering statins (which include Crestor, Lipitor and Zocor) have different side effects, he said.

The new research, published in the Nov. 24 issue of the Archives of Internal Medicine, received funding from the American Heart Association, as well drug makers Amgen and GlaxoSmithKline, which makes Avandia.

Page:  1 | 2 | 3 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 11/24/2008

Related Links
 border=
From Healthscout's partner site on heart disease, MyHeartCentral.com
Learn about heart disease symptoms.
Get more information on heart disease treatment for your health!
What can you do to prevent heart disease? Prevention details here.





SOURCES: Wolfgang C. Winkelmayer, M.D., Sc.D., assistant professor, medicine, Harvard Medical School, Boston; Eric J. Topol, M.D., director, Scripps Translational Science Institute, chief academic officer, Scripps Health, La Jolla, Calif.; Nov. 24, 2008, prepared statement, GlaxoSmithKline; Nov. 24, 2008, Archives of Internal Medicine


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy